Form 4: RA Capital Management Discloses Director Stock Option Grant in Septerna, Inc.

RA Capital Management, a significant shareholder and director of Septerna, Inc., has disclosed the grant of 16,623 stock options to director Jake Simson, exercisable at $10.24 per share.

Summary

• SEC Form 4 was filed by RA Capital Management, L.P. and related entities/individuals (RA Capital Healthcare Fund LP, RA Capital Nexus Fund III, L.P., Peter Kolchinsky, Rajeev M. Shah) concerning Septerna, Inc. (SEPN).
• The filing reports the grant of 16,623 stock options to Jake Simson, who serves as a director of Septerna and is a Partner of RA Capital Management, L.P.
• The stock options have an exercise price of $10.24 per share.
• The transaction date for the option grant was June 17, 2025, and the options are set to expire on June 16, 2035.
• The shares underlying the option will vest on the earlier of June 17, 2026, or Septerna's next annual meeting of stockholders, contingent on Dr. Simson's continued service to the company.
• Dr. Simson holds these options for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund III, with an obligation to turn over any net proceeds to RA Capital Management, L.P. to offset advisory fees.
• The reporting persons explicitly disclaim beneficial ownership of the option and underlying common stock, except to the extent of their respective pecuniary interest therein.

Sentiment

Score: 6

Explanation: The document is a neutral, factual disclosure of an insider transaction (stock option grant). While the grant itself can be seen as a positive for aligning interests, the filing itself doesn't contain performance or operational news that would significantly shift sentiment. The disclaimers of beneficial ownership are standard for such arrangements.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, potentially incentivizing long-term company performance.
• The transaction is consistent with the Issuer's Non-Employee Director Compensation Policy, indicating a structured and transparent approach to director remuneration.

Risks

• The vesting of the stock options is contingent upon Dr. Simson's continued service to Septerna, Inc., meaning the full benefit is not guaranteed if his service ceases before the vesting date.

Future Outlook

The vesting schedule for the granted stock options indicates a future milestone for the director's equity, contingent on continued service until June 17, 2026, or the next annual meeting of stockholders.

Management Comments

• "Represents the grant of a stock option to Jake Simson pursuant to the Issuer's Non-Employee Director Compensation Policy."
• "The shares subject to the option shall vest on the earlier of (i) June 17, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to Dr. Simson's continued service to the Issuer through such vesting date."
• "RA Capital Management, L.P. (the 'Adviser') is the investment manager for RA Capital Healthcare Fund, L.P. (the 'Fund') and RA Capital Nexus Fund III, L.P. (the 'Nexus Fund III')."
• "Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."
• "Jake Simson is a Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Simson's arrangement with the Adviser, Dr. Simson holds the option for the benefit of the Fund and the Nexus Fund III."
• "Dr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund III to the Adviser."
• "The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common for publicly traded companies, particularly in the biotechnology or pharmaceutical sector, to align director incentives with shareholder value. The involvement of a prominent healthcare investment firm like RA Capital Management highlights its continued strategic interest and governance role in Septerna, Inc.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard practice across various industries, including the biotechnology sector, aimed at attracting and retaining qualified board members.
• The vesting schedule, which is tied to continued service and the company's annual meeting, is a typical structure for director equity awards, designed to ensure long-term commitment.
• The specific arrangement where a director holds options for the benefit of an investment fund, with proceeds offsetting advisory fees, is a common mechanism for directors representing institutional investors, reflecting their primary affiliation with the investment firm rather than direct personal compensation from the issuer.

Corporate Governance

Related Party Transactions

• The stock option is granted to Jake Simson, a director of Septerna, Inc., who is also a Partner of RA Capital Management, L.P., a 10% owner and significant investor in Septerna.
• Dr. Simson holds the option for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund III, with any net proceeds from exercise offsetting advisory fees owed by these funds to RA Capital Management, L.P. This arrangement constitutes an indirect related party transaction where the director's compensation mechanism is tied to the investment firm's financial arrangements with its managed funds.

Stakeholder Impact

• Shareholders: The grant of stock options to a director, particularly one representing a significant institutional investor, aligns the director's financial incentives with the company's stock performance, potentially benefiting long-term shareholder value.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• The stock options will vest on the earlier of June 17, 2026, or Septerna's next annual meeting of stockholders, subject to Dr. Simson's continued service.

Key Dates

Recommendation

Keywords

SEC Form 4, Septerna Inc., SEPN, RA Capital Management, Stock Option Grant, Director Compensation, Insider Transaction, Beneficial Ownership, Equity Compensation, Investment Management